On July 28, Sanofi SA rose 3.07% in regular trading, trading at $45.6/share, with turnover of $26.29 million. The stock advanced amid broad strength in the pharmaceutical sector and anticipation of its upcoming second-quarter earnings report.

Sanofi is scheduled to release Q2 results before market open on July 30, with consensus EPS estimated at $1.09. Market participants appear to be positioning ahead of the report. Simultaneously, the broader pharma sector showed pronounced strength, with Pfizer up 3.19%, Merck up 3.16%, Johnson & Johnson up 2.78%, Eli Lilly up 2.42%, and AstraZeneca up 2.27%, reflecting clear sector-wide momentum.

Additionally, Sanofi previously announced the discontinuation of amlitelimab development for atopic dermatitis on July 24, which initially weighed on shares. However, the company explicitly stated the decision would not alter its full-year financial outlook, and the near-term negative sentiment appears to have been absorbed by the market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)